These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
332 related articles for article (PubMed ID: 16224539)
1. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. Vincent L; Kermani P; Young LM; Cheng J; Zhang F; Shido K; Lam G; Bompais-Vincent H; Zhu Z; Hicklin DJ; Bohlen P; Chaplin DJ; May C; Rafii S J Clin Invest; 2005 Nov; 115(11):2992-3006. PubMed ID: 16224539 [TBL] [Abstract][Full Text] [Related]
2. Adrenomedullin blockade induces regression of tumor neovessels through interference with vascular endothelial-cadherin signalling. Khalfaoui-Bendriss G; Dussault N; Fernandez-Sauze S; Berenguer-Daizé C; Sigaud R; Delfino C; Cayol M; Metellus P; Chinot O; Mabrouk K; Martin PM; Ouafik L Oncotarget; 2015 Apr; 6(10):7536-53. PubMed ID: 25924235 [TBL] [Abstract][Full Text] [Related]
3. Vascular disrupting effect of combretastatin A-4 phosphate with inhibition of vascular endothelial cadherin in canine osteosarcoma-xenografted mice. Izumi Y; Takagi S Res Vet Sci; 2019 Feb; 122():1-6. PubMed ID: 30439557 [TBL] [Abstract][Full Text] [Related]
4. Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability. Liao F; Doody JF; Overholser J; Finnerty B; Bassi R; Wu Y; Dejana E; Kussie P; Bohlen P; Hicklin DJ Cancer Res; 2002 May; 62(9):2567-75. PubMed ID: 11980651 [TBL] [Abstract][Full Text] [Related]
5. Effects of combretastatin A-4 phosphate on canine normal and tumor tissue-derived endothelial cells. Izumi Y; Aoshima K; Hoshino Y; Takagi S Res Vet Sci; 2017 Jun; 112():222-228. PubMed ID: 28527400 [TBL] [Abstract][Full Text] [Related]
6. Combretastatin A4 phosphate induces programmed cell death in vascular endothelial cells. Ding X; Zhang Z; Li S; Wang A Oncol Res; 2011; 19(7):303-9. PubMed ID: 21936400 [TBL] [Abstract][Full Text] [Related]
8. The influence of hypoxia and energy depletion on the response of endothelial cells to the vascular disrupting agent combretastatin A-4-phosphate. Holmes T; Brown AW; Suggitt M; Shaw LA; Simpson L; Harrity JPA; Tozer GM; Kanthou C Sci Rep; 2020 Jun; 10(1):9926. PubMed ID: 32555222 [TBL] [Abstract][Full Text] [Related]
9. The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death. Petit I; Karajannis MA; Vincent L; Young L; Butler J; Hooper AT; Shido K; Steller H; Chaplin DJ; Feldman E; Rafii S Blood; 2008 Feb; 111(4):1951-61. PubMed ID: 18024794 [TBL] [Abstract][Full Text] [Related]
10. Biological and anti-vascular activity evaluation of ethoxy-erianin phosphate as a vascular disrupting agent. Yuan W; Su C; Yang X; Li Y; Cao Y; Liang X; Liu J J Cell Biochem; 2019 Oct; 120(10):16978-16989. PubMed ID: 31111562 [TBL] [Abstract][Full Text] [Related]
11. The novel Src kinase inhibitor M475271 inhibits VEGF-induced vascular endothelial-cadherin and beta-catenin phosphorylation but increases their association. Ali N; Yoshizumi M; Yano S; Sone S; Ohnishi H; Ishizawa K; Kanematsu Y; Tsuchiya K; Tamaki T J Pharmacol Sci; 2006 Sep; 102(1):112-20. PubMed ID: 16974068 [TBL] [Abstract][Full Text] [Related]
15. Desacetylvinblastine Monohydrazide Disrupts Tumor Vessels by Promoting VE-cadherin Internalization. Lei X; Chen M; Huang M; Li X; Shi C; Zhang D; Luo L; Zhang Y; Ma N; Chen H; Liang H; Ye W; Zhang D Theranostics; 2018; 8(2):384-398. PubMed ID: 29290815 [TBL] [Abstract][Full Text] [Related]
16. Green tea catechins inhibit VEGF-induced angiogenesis in vitro through suppression of VE-cadherin phosphorylation and inactivation of Akt molecule. Tang FY; Nguyen N; Meydani M Int J Cancer; 2003 Oct; 106(6):871-8. PubMed ID: 12918064 [TBL] [Abstract][Full Text] [Related]
17. Combretastatin A4 phosphate. West CM; Price P Anticancer Drugs; 2004 Mar; 15(3):179-87. PubMed ID: 15014350 [TBL] [Abstract][Full Text] [Related]
18. Transcatheter Arterial Embolization Combined with Anti-vascular Agent Combretastatin A4 Phosphate Inhibits Growth and Vascularization of Liver Tumor in an Animal Model. Zhao H; Wu ZZ; Ren Q; Wu JJ; Wang Y; Feng JW; Rao M; Deng Q; Hu HY Curr Med Sci; 2022 Dec; 42(6):1240-1247. PubMed ID: 36462132 [TBL] [Abstract][Full Text] [Related]
19. The first study on therapeutic efficacies of a vascular disrupting agent CA4P among primary hepatocellular carcinomas with a full spectrum of differentiation and vascularity: Correlation of MRI-microangiography-histopathology in rats. Liu Y; De Keyzer F; Wang Y; Wang F; Feng Y; Chen F; Yu J; Liu J; Song S; Swinnen J; Bormans G; Oyen R; Huang G; Ni Y Int J Cancer; 2018 Oct; 143(7):1817-1828. PubMed ID: 29707770 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4. Griggs J; Skepper JN; Smith GA; Brindle KM; Metcalfe JC; Hesketh R Am J Pathol; 2002 Mar; 160(3):1097-103. PubMed ID: 11891206 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]